Kornimate/medical-research-clean huggingface dataset:
fall risk assessment in people with diabetic neuropathy

Conditions: Diabetic Peripheral Neuropathy

Summary: fall risk is increased in people with diabetic peripheral neuropathy (dpn) and yet, minimal research has been conducted to identify appropriate fall risk assessment tools and improve our understanding of falls in these individuals. purpose: the primary purpose of this study is to establish a foundation of knowledge needed to address falls in people with dpn. this will be accomplished through 1) comparing the validity of 4 fall risk assessment tools, 2) identifying risk factors for falls and 3) determining how quality of life is influenced by factors related to falls in people with dpn.

all subjects participate in testing that involves questionnaires, cognitive testing, fall risk assessment, and other testing related to physical parameters including body mass index, glycosylated hemoglobin, lower extremity nerve conduction study, and ankle range of motion, proprioception and strength. after testing, subjects are interviewed to determine fall status (faller or non-faller). a "faller" is defined as someone that has fallen at least 2 times in the past year. data analysis: the validity of the fall risk assessment tools will be compared using sensitivity and specificity analyses. variables related to ankle function, neuropathy, glycemic control and general activity will be analyzed for association with recent fall history through multivariable logistic regression. variables related to falls, neuropathy and activity level will be analyzed for association with health-related quality of life through multivariable linear regression.

Eligibility criteria:
inclusion criteria: * diagnosed with diabetic peripheral neuropathy exclusion criteria: * major medical depression * non-diabetes related musculoskeletal problems that limit ambulation * open wounds on the weight bearing surfaces of the feet * requires another person's assistance to walk * uncorrected visual deficits that influence gait and/or balance * history of stroke or other cns pathology that impairs gait and/or balance * diagnosed untreated vestibular disorder that results in gait and/or balance disturbances

Keywords: neuropathy diabetes
evaluation and monitoring of the protocol post operative atrial fibrillation

Conditions: Post Operative Atrial Fibrillation

Summary: objectives the aims of this study is to evaluate the efficacy and tolerance of our post-operative af management protocol after cardiac surgery, including beta-blockers, digoxin, amiodarone. methods this study concerns patients from brest university hospital who underwent cardiac surgery between november 2019 and november 2021. patients with a previous history of atrial arrhythmias were excluded. the primary endpoint is assess effectiveness of service protocol to maintain cardiac frequency below. 110 bpm. the secondary endpoints included hemodynamic tolerance and outcomes.

background atrial fibrillation (af) is the most common complication after open heart surgery. its reported incidence is about 30%, and it is associated with a significant increase rate of thromboembolic events, respiratory failure, a longer lenght of stay in hospital and mortality. (1 ;2) gillinov's study has shown equivalent effectiveness of a rhythm control and rate control strategy, in af patients after cardiac surgery, with increased side effects in patients treated with rhythm control agents. (3) the introduction of beta-blockers can be poorly tolerated hemodynamically in patients hospitalized in intensive care unit, unless untroducing a cardio-selective beta-blocker.. methods patients who underwent a cardiac surgery from novembre 2019 to novembre 2021 were included. patients with a previous history of atrial arrhythmias were excluded. the primary endpoint is assess effectiveness of service protocol to maintain cardiac frequency below. 110 bpm. the secondary endpoints included hemodynamic tolerance and outcomes.

Eligibility criteria:
inclusion criteria: * poaf after cardiac surgery non-opposition formulated exclusion criteria: * pregnant woman opposition hemodynamic unstability with inotropic drugs or ci\<2 l/min/m2
atherosclerosis in juvenile mixed connective tissue disease (actid)

Conditions: Carotid Atherosclerosis

Summary: this study investigates presence of preclinical atherosclerosis in patients with juvenile mixed connective tissue disease in norway.

patients and controls are examined with carotid ultrasound, venous blood is drawn, and they undergo a clinical examination.

Eligibility criteria:
inclusion criteria: * diagnosis of mixed connective tissue disease exclusion criteria: -
perioperative treatment of hepatoid adenocarcinoma of stomach

Conditions: Hepatoid Adenocarcinoma of Stomach

Summary: the goal of this clinical trial is to learn if treatment modality including disitamab vedotin （rc48）, oxaliplatin，tegafur,gimeracil and oteracil porassium capsules （sox）and sindillimab works to treat locally advanced hepatoid adenocarcinoma of stomach. it will also learn about the safety of this modality. the main aim it aims to achieve are: * to evaluate the perioperative efficacy of rc48 combined with sindillizumab and sox in the treatment of locally advanced her2-expressing hepatoid adenocarcinoma of stomach * to evaluate the safety and long-term benefits of rc48 combined with sindillizumab and sox regimens in perioperative treatment of locally advanced her2-expressing hepatoid adenocarcinoma of stomach participants will: * preoperative treatment with rc48, sox and sindillizumab for 4 cycles * radical surgery after 4-6 weeks of the preoperative treatment * adjuvant treatment with rc48, tegafur,gimeracil and oteracil porassium capsules and sindillizumab for 4 cycles


Eligibility criteria:
inclusion criteria: * the histological type of gastric hepatoid adenocarcinoma was confirmed by pathological biopsy； * her2 expression (immunohistochemistry: 1+,2+,3+); * patients with clinical stage ii-iii; * those who are expected to complete r0 excision; * ecog score 0\~1; * generally in good condition, perioperative treatment and surgical resection can be tolerated; * patients were enrolled voluntarily. exclusion criteria: * combined with other malignant tumors (excluding thyroid papillary carcinoma, facial basal cell carcinoma and other low-grade malignant tumors); -patients with obstruction, bleeding, etc. who need surgical intervention after evaluation by clinicians; * dmmr/msih status； * received other anti-tumor therapy before enrollment.

Keywords: her2 sox pd-1 inhibitor disitamab vedotin perioperative treatment
the impact of baseline visual acuity on the treatment outcomes in patients treated with aflibercept in real-life clinical setting

Conditions: Wet Macular Degeneration

Summary: the study will assess the mean change in visual acuity (va) (overall and stratified by baseline va) at year 1 and 2 of treatment with aflibercept in real-life setting. in addition, the study will ascertain the baseline va in treatment -naïve wet age-related macular degeneration or neo-vascular amd (wamd) patients who start treatment with aflibercept in a real-life setting and it will assess the impact of baseline va on the outcomes of aflibercept treatment.


Eligibility criteria:
inclusion criteria: * treatment-naïve eyes with neovascularization amd, with the indication to be treated with aflibercept. one and/or two eyes per patient. exclusion criteria: * eyes treated previously with another anti-vegf drug.
individual molecular mrd monitoring for mds patients after allo-sct

Conditions: MDS; SCT; MRD

Summary: this study aims to develop highly sensitive methods for early detection of relapse based on the patients unique mutations. initially, a mutational screen is being performed. primers directed against these mutations will be constructed and presence of mutations will be followed in bone marrow and blood frequently after transplantation.

this study aims to develop highly sensitive methods for early detection of relapse based on the patients unique mutations. screening of mutations in collaboration with department for clinical genetics, uppsala, an initial screening of mutations will be performed using the commercial truesight© sequencing panel which includes 54 genes recurrently mutated in myeloid diseases. based on the mutations identified, pcr-primers for all patient-specific mutations will be designed. patients without any mutation will be excluded from the study. the mutational screen is performed as soon as a patient is being identified as a potential candidate for allogeneic stem cell transplantation (sct) and evaluated for most optimal pre-sct treatment. the patient is included in the study before the bone marrow sampling preceding sct. in case a mutational screen has not been performed before pre-sct mds treatment, a mutational screen from the diagnostic national biobank sample (peripheral blood) can be performed. mrd surveillance after the transplantation, peripheral blood samples will be collected once monthly; and bone marrow samples will be collected at month 1, 3, 6 after sct followed by sampling every third month until relapse or death. the samples are sent to biobanking and molecular resource infrastructure of sweden (bbmri) who will extract dna and store the samples. by using the highly sensitive digital-pcr method the investigators will determine the size of the different clones at the different time points. in addition to biobanking of dna, bbmri will collect and vital froze mononuclear cells (mncs) to be used for experimental studies. statistics landmark analyses will be performed at different time points after sct, using presence of mrds as a risk factor included in a multivariate analysis. furthermore, the investigators will calculate sensitivity, specificity and predictive value for mrds in relation to relapse. for each specific mutation, with high enough frequency in the cohort, the investigators will define cut-off values of the mrd where relapse is impending.

Eligibility criteria:
inclusion criteria: 1. mds with allo sct to be performed 2. one or more mutations identified 3. written informed consent exclusion criteria: -
establish a specific cohort database for depressive disorders

Conditions: Depressive Disorder

Summary: depression is characterized by high prevalence, high recurrence rate, high disability rate, high suicide rate, and heavy disease burden. however, the diagnosis, treatment, and prognosis of depression are difficult to meet the clinical needs at present. this study plans to integrate a large sample of hospital clinical data, laboratory examination data, brain imaging, and electrophysiological data, as well as audio-visual data, to establish a database for depressive disorder, and long-term follow-up to form a specific disease cohort. this study will provide a scientific basis for exploring biomarkers related to objective diagnosis and treatment of depression.

together with three tertiary hospitals in shanghai, shanghai tenth people's hospital, renji hospital affiliated to shanghai jiaotong university school of medicine, and zhongshan hospital affiliated to fudan university, shanghai mental health center will take a lead to establish a big database focused on depressive disorders. expert consensus will be used to determine the standard for the dataset. real-world data will be include. to establish a depressive disorders-specific database with multiple functions, such as data insight, data retrieval, cohort project establishment, follow-up, and statistical analysis.

Eligibility criteria:
inclusion criteria: * age 18-75 * meeting icd-10 depressive episode criteria (f32, f33, f34, f38, f39) * cultural, social and educational background sufficient to understand informed consent and research content * agree to participate in this study exclusion criteria: * exclude other mental disorders such as bipolar disorder and schizophrenia (but not comorbidities) * patients with a history of brain injury or cerebrovascular accident, myocardial infarction, severe liver cirrhosis, acute and chronic renal failure, severe diabetes, aplastic anemia, moderate and severe malnutrition and other serious physical diseases of the nervous, heart, liver, kidney, endocrine and blood systems

Keywords: depression cohort study database
treatment of overweight in general practice

Conditions: Overweight and Obesity; Nutritional and Metabolic Diseases

Summary: in this study the investigators want to explore the feasibility and effect of a simple intervention provided by primary care physicians on treatment for overweight in general practice. regular patients visiting their ordinary family physician will be asked for participation if they comply with the inclusion criteria. if so, they will follow a detailed food list for 12 months with regular visits to the doctor. at each visit, the participating patients will be asked about their progress on weight loss and all measurements will be made. simultaneously a control group of primary care physicians will also recruit patients that fulfill the inclusion criteria. these patients will also provide data that will serve as control to the intervention group.

the number of patients with overweight is increasing and a daily issue in general practice. many patients wish to discuss their weight problem with their family physician but many of these feel helpless to guide their patients in how to reduce weight. providing useful and correct information should not be so difficult but many doctors choose to refer their patients to dietary courses or follow-up in specialist health care.in this study the investigators wish to implement a simple tool for treatment of overweight in primary care by providing the patients a detailed list for all meals that will ensure a weight loss. the patients will be given a close follow-up by their doctor, and the motivating conversation and list of meals will be the only treatment given. the study is a cluster randomised controlled trial where all general practices in the area of moss city in norway will be asked to participate. half of the physicians will constitute the intervention group while the other half will serve as control group. each participating doctor in both groups will recruit patients according to the eligibility criteria. the doctors in the intervention group will be provided with a course to learn the intervention and have a manual to follow for each patient. all participating patients of both groups will be asked to meet regularly for data collection. according to the power calculation, a number of 12 physicians in each group will be sufficient if they recruit 10 patients each. the intervention will be conducted for 12 months and thereafter data will be continued to be collected at 6 and 12 months after.

Eligibility criteria:
inclusion criteria: * bmi _\> 30 or _25 with at least one medical condition related to overweight (hypertension, dyslipidemia, metabolic syndrome, diabetes mellitus ii, hip- or knee pain) * written consent * sufficient knowledge in norwegian language to acquire the written and oral information exclusion criteria: * any ongoing cancer condition * any current medication impacting on weight

Keywords: overweight, general practice
the effects of oxytocin on affective touch

Conditions: Healthy

Summary: the main aim of the study is to investigate whether intranasal oxytocin (24iu) increases the affective processing of touch in general or whether it's effect vary according to the affective valence of the touch (positive, neutral, negative). moreover, associations with trait autism will be explored.

a double-blind, within-subject, placebo controlled design will be employed in this study. in a randomized-order a total of 40 healthy male subjects will receive oxytocin- and placebo-nasalspray (interval between the administration \> 2 weeks). 45 minutes after treatment subjects will be administered the touch-stimulation to the dorsal forearm by a trained experimenter (lengths: 8cm, rate 8cm/s). after each block of stimulation, the subjects will be asked to rate their subjective experience of the touch.the neural basis of touch processing will be measured via simultaneously acquired fmri. levels of trait autism will be assessed using the autism spectrum quotient (asq) and related scales such as the empathy quotient (eq), liebowitz social anxiety scale (lsas), or the sensory over responsivity scale (sor) and under responsively scale (urs).

Eligibility criteria:
inclusion criteria: * healthy subjects without any past or present psychiatric or neurological disorders exclusion criteria: * history of brain injury medical or mental illness

Keywords: oxytocin affective touch trait autism
pulmonary health in children with down syndrome

Conditions: Down Syndrome; Dysphagia, Oropharyngeal

Summary: the goal of the study is to learn more about tests that can assess lung health in children with down syndrome.


Eligibility criteria:
inclusion criteria: * children aged 3 to 18 years, inclusive, at time of consent * diagnosis of down syndrome/trisomy 21 or mosaicism * able to walk * had a swallow study (video fluoroscopic swallow study or fiberoptic endoscopic evaluation of swallowing) performed within 5 years of consent date exclusion criteria: * pregnant or lactating * nonambulatory * have a tracheostomy or other known severe glottic or subglottic obstruction that would significantly affect the results of testing * have a significant acute respiratory illness, defined as treatment with steroids, antibiotics, or an increase in supplemental oxygen * have a medical illness that would a)increase the risk the participate would incur by participating in the study, b) interfere with the outcomes of the study, or c) interfere with the performance of study participants * have a severe behavioral problem that would interfere with the performance of study procedures

Keywords: oscillometry spirometry outcomes
ocular surface changes in patients with cystic fibrosis

Conditions: Eye Manifestations

Summary: cystic fibrosis(cf) is an inherited disease affecting children, adolescents and young adults with dysfunction of secretory glands.it is caused by mutations in the protein-coding gene which function as the cystic fibrosis transmembrane regulator (cftr), responsible for the secretion of chloride ions in epithelial cells, adenocytes, sweat gland cells, pancreatic ducts,alimentary and respiratory tracts and eye. assessment of the relationship between the inflammatory processes and apoptosis in the eye in the course of cystic fibrosis will allow determination of immunological exponents which may facilitate diagnosis.

the aim: to assess the role of chosen parameters of immunological response in the induction of ocular changes in cystic fibrosis patients, particularly chosen chemokine concentrations in the tear fluid and analysis of chosen apoptotic markers expression on conjunctival epithelial cells.

Eligibility criteria:
inclusion criteria: * male and female patients aged 3-25 with clinically definite diagnosis of cystic fibrosis * all patients must give written consent for participation in the study at screening exclusion criteria: * patients with a history of chronic disease of the immune system * patients with the history of systemic diseases * patients with the history chronic ocular diseases * patients who have been treated with corticosteroids in the past 3 months prior to the screening visit

Keywords: cystic fibrosis eye inflammation apoptosis c11+
improving symptoms of schizophrenia and schizoaffective disorder by supplementing medications with pravastatin

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: this study supplements patients' current medications with pravastatin, a cholesterol-lowering medication, to try to improve residual symptoms of schizophrenia, and also to improve cognitive functioning.

this study supplements patients' current medications with pravastatin, a cholesterol-lowering medication, to try to improve residual symptoms and also to improve cognitive functioning. it consists of 15 total study visits over a 28-week period of time, one visit every 2 weeks. blood draws will be done once every 4 weeks throughout the study to monitor lipid levels, c-reactive protein, ast, alt, and cpk total. cognitive testing will be completed at the beginning of the study and at the end of the study. during the study visits, the staff will be monitoring vitals signs (weight, height, blood pressure, pulse, waist/hip ratio), possible side effects, positive and negative symptoms, mood symptoms, and overall functioning.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia or schizoaffective disorder * male and female subjects; age 18-65 years inclusive * ability to provide informed consent * no psychiatric hospitalization in the last 30 days prior to randomization * panss score at study entry between 80 and 120 inclusive, or those who continue to experience some residual positive and/or negative symptoms and are not at their baseline level of functioning. * current psychiatric medications stable for at least 30 days * currently receiving only one antipsychotic medication * female subjects of child-bearing age must use an acceptable method of birth control exclusion criteria: * active, uncontrolled, or chronic liver disease * heart failure * current alcohol abuse or dependence * female subjects who are pregnant, lactating or plan to become pregnant during the study period * history of allergic reaction with any statin in the past * kidney disorder or other evidence of renal dysfunction * uncontrolled diabetes * untreated hyperlipidemia * concurrently receiving treatment with cyclosporine, gemfibrozil, clofibrate, fenofibrate, niacin, macrolide antibiotics, erythromycin, hiv protease inhibitors, nefazodone, or verapamil

Keywords: schizophrenia schizoaffective disorder positive symptoms negative symptoms cognitive functioning pravastatin